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ANTICONVULSANT DRUGS. Volume 1. International Encyclopedia of Pharmacology
and Therapeutics, Section 19, J. Mercier (Section editor); Pergamon Press, Oxford,
1973. 402 pp. $28.50.
This volume is the first half of the anticonvulsant drug section of the I.E.P.T.,
which is sponsored by the International Union of Pharmacology and is intended to
provide comprehensive compendia of basic and clinical information about major
drug groups. In general, the goal is achieved here. The latter half of the book con-
sists of four excellent chapters on laboratory-clinical correlations, structure-
activity relationships, and pharmacokinetics in animals and man. These chapters
are densely referenced, for the most part well organized, and contain adequate his-
torical perspective; together they constitute a valuable reference for phar-
macologists and clinicians. The book's first four chapters are less satisfactory. The
first of these is a review of the classification and presumed pathophysiology of
epileptic seizures. The material presented is all available elsewhere, and much of it
has been published repeatedly. One can question whether any useful purpose is
served by presenting it again in. a pharmacological reference work which is likely to
be used most by people who have more extensive treatment of these subjects ready
at hand. The three succeeding chapters on methods for assessing anticonvulsant
activity of drugs are too long; one of them is filled with unpublished personal data
and rambling discussions ofmatters remote from pharmacology.
This volume covers much of the same ground as Antiepileptic Drugs, Woodbury,
et al. (eds.) and Experimental Models ofEpilepsy, Purpura et al. (eds.). However,
there is enough difference in content that a research worker in this area will want ac-
cess to all three books. A clinician in need of a single work for occasional reference
will be best served by the present volume.
J. W. PRICHARD
Department ofNeurology
Yale UniversitySchoolofMedicine
THE PERSECUTED DRUG. THE STORY OF DMSO. By Pat McGrady, Sr. Doubleday
and Co., New York, 1973. viii, 372 pp. $7.95.
An inexpensive panacea repressed by a federal agency, a selfless dedicated phy-
sician dedicated to his patients. There are theingredients ofa book on the recent for-
tunes ofdimethylsulfoxide. There are good guys (physicians), bad guys (the govern-
ment, FDA), losers (patients), and winners (big business). The roles are as rigidly
defined as in a Hollywood western but that is not to say that westerns are not
entertaining. They are, and so is the book by Pat McGrady, a good story teller who
was the science editor of the American Cancer Society. His metier is the essay-the
short exposition, and the book would probably be best enjoyed as a series of inter-
rupted readings? The book is divided into five sections. These divisions do not reflect
any obvious attempt at organization in theusual sense; however, each ofthe five sec-
tions is lively, entertaining, and can be read as a free-standing essay. The book is less
than the sum of its five parts. The only theme that integrates the parts are the too
obvious type-cast roles described earlier. In the words of the author Pat McGrady
(adjectives his) ". . . the purchaser ofthis book gets not a single, simple, straightfor-
ward account of a drug but three stories in one: the incredible performance ofan un-
believable drug; the unlikely adventures of a fantastic government agency; and the